[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"soft-tissue-sarcoma-of-the-limb\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:soft-tissue-sarcoma-of-the-limb":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100631983","phase-2-assessment-of-the-long-term-efficacy-of-moderately-hypofractionated-neoadjuvant-radiotherapy-soft-tissue-sarcoma-in-the-limbs-or-trunk-wall-100631983",false,"NCT07507773","Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall","Phase II Clinical Trial Assessing the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall, Incorporating Translationnal Research","NEORASARC","Inclusion Criteria:\n\n* Patient aged ≥ 18 years ;\n* Localised sarcoma of a limb, the root of a limb, or the trunk wall ;\n* Histologically confirmed diagnosis of soft tissue sarcoma regardless of the grade ;\n* Diagnosis biopsy performed at Centre Oscar Lambret, with specimen available for translational research ;\n* Indication of neoadjuvant radiotherapy according to the multidisciplinary consultation meeting ;\n* Tumor considered operable with a curative intent and conservative intent according to the multidisciplinary consultation meeting ;\n* Affiliation to the French National Social Security System ;\n* Informed and signed consent\n\nExclusion Criteria:\n\n* Metastatic disease (including local lymph node diffusion) ;\n* Visceral or retroperitoneal sarcoma ;\n* Tumor considered inoperable even after radiotherapy, according to the multidisciplinary consultation meeting ;\n* Indication of neoadjuvant or adjuvant chemotherapy ;\n* Ewing tumor of soft tissue, desmoid tumor, embryonal or alveolar rhabdomyosarcoma ;\n* Pregnant or breastfeeding women ;\n* Patients under protective measures ;\n* Patient refusal.","ALL","18 Years",{"count":20,"type":21},135,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This trial aims to assess the long-term efficacy of moderately hypofractionated neoadjuvant radiotherapy for soft tissue sarcoma in the limbs or trunk wall. The primary outcome is local disease control, assessed by the cumulative incidence of progression\u002Frecurrence.\n\nAfter informed consent has been obtained and eligibility criteria have been checked, a baseline assessment will be performed followed by the experimental treatment: intensity-modulated radiotherapy with a moderately hypofractionated regimen consisting in 15 fractions of 2.7 Gy administered over 3 weeks.\n\na follow-up assessment will be performed 3 to 4 weeks after the last radiotherapy session.\n\nTumor resection will be performed 4 to 8 weeks after the radiotherapy. Patients will then be followed up until the end of the study; planned 5 years after the last inclusion.\n\nRadiotherapy will be evaluated in terms of safety and efficacy.",[27,28,29,30],"Soft Tissue Sarcoma Adult","Soft Tissue Sarcoma (Excluding GIST)","Soft Tissue Sarcoma of the Trunk and Extremities","Soft Tissue Sarcoma of the Limb",[32,33,34,35,36],"Sarcoma","Trunk","Limb","Radiotherapy","Neoadjuvant","RECRUITING","2026-06-18",{"date":40,"type":41},"2026-06-22","ACTUAL",{"date":43,"type":21},"2026-06-01",{"date":45,"type":21},"2035-06-01",{"name":47,"class":48},"Centre Oscar Lambret","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":70,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":49},"100626230","precision-medicine-approaches-for-neoadjuvant-therapy-in-high-risk-sarcoma-patients-100626230","NCT07432932","Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients","PANTHR-S","Inclusion Criteria:\n\n* Written informed consent for the prospective cohort\n\n  * Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval.\n  * High-risk sarcoma definition:\n\n    * Greater than 5cm or Grade 3\n    * Deep anatomic location\n  * Have disease amenable to biopsy\n\n    o Patients who are not amenable to repeat biopsy at baseline can be reviewed with the local site PI for consideration of inclusion to the study\n  * Resectable tumour\n  * Measurable disease by RECIST 1.1\n  * Aged ≥ 18 years\n  * WHO performance status 0-2\n  * For patients receiving NCT, medically fit enough, with adequate organ function, to undergo neoadjuvant chemotherapy\n  * Patients medically fit enough to undergo surgical resection\n  * Capable of giving written informed consent (for prospective cohort) and comply with the study schedule\n  * Patients may also participate in the STRASS 2 trial\n\nExclusion Criteria:\n\n-Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI.\n\n* Known additional malignancy that is progressing or requires active treatment\n* Metastatic disease not amenable to curative intent local therapy\n* Any active uncontrolled medical conditions",{"count":58,"type":21},800,"OBSERVATIONAL","This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), vascular sarcomas, malignant peripheral nerve sheath tumour (MPNST) or other subtypes. It comprises of both retrospective and prospective tissue collection from patients advancing directly to surgery (control group) and patients receiving NCT and surgery.",[32,62,63,64,27,29,30,65,66,67,68,69],"Sarcoma, Leiomyo-, Adult","Sarcoma, Synovial, Adult","Soft Tissue Sarcoma (STS)","Retroperitoneal Sarcoma","Liposarcoma, Dedifferentiated","Liposarcoma","Leiomyosarcoma (LMS)","Angiosarcoma",[71,72,73],"PANTHRS","PANTHRS-S","Sarcoma Accelerator","2026-02-18",{"date":76,"type":41},"2026-02-25",{"date":78,"type":41},"2021-11-19",{"date":80,"type":21},"2028-06-30",{"name":82,"class":48},"Royal Marsden NHS Foundation Trust"]